Exaptation, the preadaptation of technologies for unintended functions, is an important mechanism in the expansion of the technosphere. In this paper we propose a method to measure the frequency of exaptation. We apply it to the pharmaceutical sector and offer the first measure of the frequency of exaption in an industry. We show that exaptation accounts for about half of all innovations in the uses of drugs. We also show that some exaptations have a radical character and trigger cascades of innovation.
Introduction
Innovation is a novel recombination or transformation of resources and ways of using them that creates value through a match to consumers´ needs and wants. Most of the research on innovation has focused on innovation as New Product Development and assumed that value is predominantly created through the introduction of new products (or services). With a few exceptions firms have also followed that pattern -new products have been matched to and equated with a single market.
In this paper, we propose an alternative approach -we anticipate that some products introduced for a specific market will later become used to address different needs or wants in a different market.
Importantly, we posit that this emergent functionality is an innovation because it creates value in a novel way even if the product remains the same.
This alternative view can have implications for how organizations invest in innovation and extract value from their inventions. Latent product functionality can also enable organizations to adapt to changing environments thus making them sustainable and resilient. A product that was adapted for a specific market condition may have a different functionality that can be exploited if the original market disappears. In fact, an analogous version of this process of innovation exists in evolutionary biology and is termed 'exaptation' -a name that we borrow in this paper. It is defined as "the process by which features acquire functions for which they were not originally adapted or selected" (Oxford Dictionary).
Anecdotal evidence shows that exaptation is important not only in evolutionary biology but also in technology development. Many technological innovations, some of which radical, have been the result of exaptation (Andriani and Carignani 2014 , Cattani 2006 , Dew et al. 2004 , Kauffman 2000 . For instance, the microwave oven resulted from the discovery of a latent function of the radar magnetron and the first amplifier was exapted from De Forrest's Audion, originally designed for radio detection (Nebeker 2009 ). Exaptation has been crucial in the emergence of new industries. The modern pharmaceutical and chemical industries emerged as the result of multiple instances of exaptation of coal tar (Andriani and Carignani 2014) .
To date, however, no study has quantified the frequency and the impact of exaptation in innovation. Is exaptation just "an interesting but minor wrinkle" in evolutionary theory as stated by Dawkins (cited in Gould 2002 , p. 1019 , or a fundamental mechanisms in the evolution of new technologies as stated by Kauffman? In this paper, we address this issue by measuring the frequency of exaptation in a specific technological sector: the pharmaceutical industry. We expect that our results, while not of the exact same size, are broadly generalizable to other industries.
Measuring the frequency of exaptation matters for several reasons. First, as noted earlier, exaptation refers to the discovery of a 'latent' functionality in an existing artefact. Measuring the frequency of exaptation can help us estimate the latent value in existing artefacts. Extracting such latent value is, theoretically, cheaper than creating new artefacts for new functionalities as the creation process itself is costly.
Second, measuring exaptation improves our understanding of radical innovation (Andriani and Carignani 2014; Levinthal 1998) and the origin of new industries. In Table 1 we report a selected list of exaptations that have shaped the evolution of the pharmaceutical industry. The table shows that many fundamental breakthroughs in drug discovery are exaptive. The first antiseptic, anesthetic, antibiotic, antidepressant, sedative, antipsychotic, anti-alcohol addiction, cancer chemotherapy agent, erectile dysfunction drug, HIV drug were not invented but exapted from products already available in the market or in laboratories. Thus, exaptation is a source of a radical innovation and triggers the emergence of new industries and scientific trajectories.
Third, our proposed methodology gives scholars a solid base to assess the importance of exaptation in innovation. The research methods utilized so far are mostly qualitative and rely on the selection of specific examples. They are therefore unable to provide a scale of the phenomenon.
Fourth, our paper decouples innovation from new product development and proposes a value based view of innovation where development of new products is not always necessary for addressing customer needs or wants. This separation of new product development from innovation implies that value can be achieved without designing new solutions as the solution may be already available. This new way of thinking can then be expanded by researching and identifying processes that can help firms extract more value from their current products.
Finally, exaptation is related to serendipity (Dew 2009; Merton 2004 ), which acts on existing entities by revealing some unforeseen possibilities and connections hidden in them. In other words, serendipity uncovers potential exaptations. Thus, a measure of the frequency of exaptation is also indirectly a measure of serendipity in innovation (Ban 2006; Comroe Jr 1977; Duffin 2000; Li 2006; Meyers 2007) . While serendipity, by definition, is not intentional, policymakers and organizations may implement processes that could "favor the prepared mind". One such process, advocated by Nobel laureate Luria is 'controlled sloppiness' in scientific research (Merton 2004, p. 192 ).
The literature shows that exaptation: a) is important in the history of multiple industries (Dew et al. 2004 ); b) affects both whole artefacts and internal modules (Andriani and Carignani 2014); interacts with adaptive processes to trigger cascades of innovations Cohen 2013, Lane 2011) ; and d) extends to technological capabilities (Cattani 2006) . All these findings show that exaptation is important. But how important is exaptation? What is the percentage of innovations due to exaptation? The evidence presented in the literature on exaptation and technological innovation is mainly anecdotal. Without a quantification that demonstrates the relevance of this phenomenon, it is difficult to argue for respectively a change in innovation policy at the macro level and a change in R&D management practices at the micro level. In this paper, we propose the first systematic measure of the frequency of exaptation in technological innovation. By applying it, we find that in the pharmaceutical industry approximately half of the new uses of existing drugs are due to exaptation.
The rest of the paper is organized as follows. In Section 2, we introduce the concept of exaptation and explain its theoretical significance. In Section 3 we describe the empirical framework.
In Section 4 and 5 we present and discuss our results. Section 6 concludes and presents some implications for innovation and organizations.
2.
Literature Review
Exaptation
Exaptation in evolutionary biology refers to biological "characters evolved for other usages (or for no function at all), and later on 'coopted' for their current role" (Gould and Vrba 1982, p. 6 ). For example, birds' wings originally served to climb trees or capture preys and they were later on coopted for flight (Gatesy and Baier 2009 ). Gould and Vrba (1982) contrasted exaptation the emergence of a new function for an existing trait with the concept of adaptation, defined as the improvement of a trait through natural selection driven by a pre-existing fitness function.
Exaptation has gained increasing attention in the innovation literature (Andriani and Carignani 2014 , Cattani 2005 , Dew et al. 2004 , Kauffman 2000 . In the innovation literature, an exaptation refers to a technology or artefact that is fit for its current function thanks to features that were selected for old functions (or no function at all) and were later co-opted for the current one.
Despite the increasing interest, the literature on exaptation is still scant. Levinthal (1998) proposes the concept of 'speciation' to explain the sudden rise of market-changing innovations. He notes that the emergence of new technology-based markets is not necessarily accompanied by a parallel process of technology development, implying that the technologies that came to define new market trajectories were often developed for different applications.
The source of exaptation lies in the discovery of 'latent functions' of existing technologies (Bonaccorsi 2011) . Dew et al. (2004) claim that the number of potential functions of any technology depends on a complex interaction between the technology and its context, which is influenced by the actions of users or inventors that try to combine the technology with new domains of use, markets and industries. This means that the total number of functions is un-prestateable and un-knowable (Felin et al. 2014 , Longo et al. 2012 . A subset of functions emerges through an adaptive channel, whereas other functions emerge through an exaptive channel. It follows that the exaptation potential is subject to combinatorial explosion and that the number of potential applications of existing technologies is
inherently larger than what designers and inventors can conceive. Cattani (2005 Cattani ( , 2006 examines whether the technological knowledge base of a firm is predominantly the result of strategic foresight or if it rather consists in 'pre-adapted' capabilities that were accumulated in the past for different applications. In particular, he shows how the accumulation of capabilities in glass production allowed glass-manufacturers such as Corning to enter the fiber optics industry, where optical glass fibers started to be used for long distance communication.
Andriani and Carignani (2014) delve into the micro-level aspects of exaptation, developing a framework for exaptation and modularity that takes into account the level at which exaptation takes place within a modular architecture. They distinguish between 'internal', 'radical' and 'external' exaptation: an internal exaptation is the exaptation of an internal module of a technology, absent any change in the function of the whole technology; a radical exaptation is the exaptation of an internal module of a technology which leads, through horizontal transfer, to the emergence of a new technology, characterized by a new function built around the exapted module; an external exaptation is the exaptation of a whole technology: a new function is discovered for it, with little or no variation with respect to the architecture of the original technology. As radical and external exaptations introduce new functions in the economy, they may give rise to radical innovations. The exaptations we study in this paper belong mostly to the external category. External exaptations are more common in the pharmaceutical industry than in other industrial sectors because drugs are non-assembled products.
The relationship between an 'adaptive' technology, i.e. developed for its current function, and an exaptive technology, developed for a function other than the current one, is complex. Exaptation, as a fundamental process of innovation, often triggers adaptive responses, which, as Jacobs (1969 Jacobs ( , 1985 shows, may become self-reinforcing and assume the character of avalanches. Levinthal (1998) theorizes about an exaptive-adaptive cycle in the context of the wireless market; Lane (2011) elaborates an adaptive-exaptive model of innovation which he calls 'exaptive bootstrapping' based on technology adoption that includes technological, organizational, and societal considerations. His model is 'adaptive-exaptive' since the innovation that activates a cascade is adaptive. In contrast, Andriani and Cohen (2013) show that in both biology and technology innovation cascades may be triggered by exaptations. These cascades are exaptive-adaptive.
Overall, previous research on exaptation has focused on theoretical aspects and has been mainly conducted through case studies (Cattani 2006) , theoretical frameworks (Andriani and Cohen 2013; Andriani and Carignani 2014; Dew et al. 2004) or computer simulations (Villani Bonacini, S., Ferrari, D., Serra, R. and Lane, D. 2007) . In this paper, we are extending this research by measuring the incidence of exaptation in an industry.
Empirical Framework

Setting
The Pharmaceutical Industry
The pharmaceutical industry and its main product drugs create an ideal setting to measure exaptations because of the existence of functional databases, entry point regulation and classification of needs. First, the pharma industry is the only one we are aware of in which drugs' functions are classified and systematized in internationally recognized databases. This allows researchers to unambiguously identify the complete spectrum of functions for which the drug is being used. Second, drugs' access to market is heavily regulated whereas their subsequent uses are not. Entry point regulation implies that the initial drug function is uniquely specified and can therefore be used as a benchmark vis-a-vis the subsequent functions that emerge through off-label uses. Third, needs in this case diseases are also uniquely classified in international databases. In short, these three properties of the industry enable researchers to discriminate between adaptive and exaptive functions.
The former is defined as functions for which the drug was developed. The latter refers to latent functions in existing drugs, which do not drive drug development and apply to markets different from the adaptive one
Drugs' Route to Market
FDA Regulation. The FDA, the agency of the US Department of Health and Human Services responsible for the protection of public health through the regulation of food, tobacco-related and pharmaceutical products, regulates the pharmaceutical industry by approving selected drugs for specific uses. In order to determine the approved function of a drug, the FDA reviews clinical trial results submitted by companies. If these results show that a drug is safe and efficacious for a particular disease, then the drug is approved for that use.
Off-Label Prescriptions. Once drugs are FDA-approved, they enter the market. As with every other artefact, availability radically expands the range of agents (such as clinicians, patient and other pharma companies) experimenting with the artefact and this engenders innovation (DeMonaco et al. 2006 ). Experimentation yields new uses for drugs, called off-label uses because these specific uses are not officially evaluated and approved by the FDA. Doctors are allowed to prescribe drugs for off-label uses, but pharmaceutical companies are barred from advertising them (Ventola 2009 ).
In the US, off-label prescriptions account for about 21% of all prescriptions on average but in some fields, such as cardiac medications and anticonvulsants, this can go up to 46% (Radley et al. 2006) . Considering that, in 2011, US spending for prescription drugs was about $322 billion (Anon 2012) , the off-label drug market can be tentatively estimated at $68 billion.
Off-label constitutes an important innovation channel in the pharmaceutical sector. In a seminal paper, DeMonaco et al. (2006) find that about more than half of off-label uses are discovered by users (and not by manufacturers). Furthermore, they find that user-led innovation is characterized by a higher degree of functional novelty. Despite its obvious importance, research on off-label is curiously minimal and the earliest paper to systematically quantify the market was only published in 2006 (Radley et al. 2006 ).
Sample
Our sample consists of the new molecular entity drugs (NMEs) approved by the FDA in 1998.
On average, the FDA approves 27 such drugs per year typically for a single use (Roin 2014 ). In 1998 the FDA approved 29 relevant NMEs (the total number of approved NMEs was 30 but one of them was a radioactive imaging agent used for diagnostic purposes and not to treat disease).
We chose the 1998 sample to allow for comparability with the DeMonaco et al. (2006) paper that looks at the role of clinicians in the discovery of off-label uses. Although their paper had a different purpose and used different methods from ours, some indicators overlap thereby providing an indirect validation of some of our results.
Measures
On Exaptation and Functional Novelty
Measuring exaptation involves an assessment of the functional novelty between two uses of the same artefact. The original (adaptive) use is the one for which the drug was developed and subsequently approved by the FDA. The emergent function represents a new use different from the one the drug was developed for. The question is whether the new use is sufficiently different from the original one to claim that the artefact's functional space has bifurcated and an exaptation has occurred.
Theoretically, function is a difficult concept to define unequivocally (Vermaas and Houkes 2006, De Winter 2010) . As a result, one can approach functional novelty in two different ways: either on the basis of designers' intentionality (in our case pharmaceutical companies) or on the basis of users' selection (such as clinicians). In the first case, where function is defined based on intentionality, exaptation can be defined in terms of deviation from designers' intentionality. But intentionality is difficult to trace and document accurately.
In the second case, functional novelty is assessed in terms of a change in users' selection, which then generates a new or modified market for the artefact. In this case, exaptation is assessed by a comparative analysis of the characteristics of the original and the exapted market. The latter is the approach we use in this paper. Therefore, in this paper we define exaptation in terms of deviation of users' selection from the original function.
Assessing Exaptation by Measuring Distance
The approach we use to measure exaptation is based on the calculation of the 'distance'
between the FDA-approved use (s) and the off-label use (s). A widely used tool for the identification of drug uses is the commercial database DrugDex (developed by MicroMedex). DrugDex is a weekly updated comprehensive compendium of drugs and includes FDA-approved and off-label uses. The inclusion of new uses in DrugDex is based on the review of the available literature published in peerreviewed journals and other sources, such as FDA documents, regulatory standards, professional health organizations, and so on.
The distance between FDA and off-label uses is measured by mapping the uses onto the 'gold standard' of disease classification, i.e. the World Health Organization's International Classification of Diseases.
To be more precise, we use the ICD-9 Clinical Modification (known as ICD-9-CM). It is a version modified by the U.S. National Center for Health Statistics (NCHS) and is currently the standard diagnostic tool for epidemiology, health management and clinical purposes in the US. It maps diseases to corresponding broader categories that group them on the basis of anatomy and pathogenesis. The classification forms a tree-like structure. Each disease is assigned a code, which can be up to five characters, where the first characters define the most generic category and the following characters progressively place the disease inside more specific baskets (subcategories).
An intuitive idea of the measure of distance is provided in figure 1 . Tolcapone is FDAapproved for Parkinson's disease and is used off-label for depression. Parkinson's disease is assigned code 332 in the ICD-9-CM and is part of sub-class 330-337 ('hereditary and degenerative diseases of central nervous system'), which belongs to class 320-389 ('diseases of the nervous system and sense organs'). The ICD-9-CM assigns the code 311 to depressive disorders, which are included in subclass 300-316 ('neurotic disorders, personality disorders, and other non-psychotic mental disorders').
In turn, the 300-316 subclass is part of the 290-316 ('mental disorders') class. Both 320-389 and 290-316 are part of the 001-999 total set of diseases and injuries. The distance is assessed by measuring the path on the ICD-9-CM between the FDA-approved and the off-label uses.
<<< Please insert Figure 1 about here >>>
In order to measure the distance, we followed these steps (details are shown in figure 2):
A. We obtain from DrugDex, for each NME, the text strings describing the FDA and off-label indications. In general, each NME is associated with one or more FDA-approved uses and multiple off-labels uses. We exclude from the analysis those off-label uses classified by DrugDex as ineffective. The FDA-approved uses correspond to our originally approved uses, whereas the off-label uses correspond to post market-introduction emergent uses.
B. We match both FDA and off-label indications to their underlying diseases as reported in the International Classification of Diseases, version ICD-9-CM.
C. In order to calculate the distance between the FDA-approved use and an off-label use, we count the number of bifurcations that separate the FDA-approved code from the off-label code in the ICD-9-CM (see figure 1 for an example). We weigh the bifurcations according to the level at which they are located within the nested tree structure. A higher level bifurcation (first or second digit in the string) indicates a partition in more general and distant classes than a lower level one. Therefore, we assign a weight of 0.5 to the first-order bifurcation, and 0.25 to the second-order and so on. In general, each DrugDex use may map onto one or more disease codes in the ICD-9-CM database. To avoid cases of multiple counting, we consider for each DrugDex use (FDA and off-label) all the possible pairs of FDA-off label codes, calculate the distances between them and then select the minimum distance. Therefore, a conservative choice is made since a shorter distance is less likely to be classified as an exaptation.
D. The threshold to discriminate between adaptive and exaptive uses is set at the second bifurcation level of the ICD-9-CM. Although the choice of the threshold is somewhat arbitrary we feel that our decision is reasonable and conservative for the following reasons: The distance method suffers from some disadvantages that are inherent in the ICD-9-CM classification:
1. It may erroneously classify an off-label use as an exaptation due to insensitivity to mechanism of action. For example, a drug used to treat a collateral symptom such as pain associated with cancer may be classified in the 'neoplasm' category and hence appear as an anticancer drug.
The opposite case is also possible: uses classified in the same subcategory (hence low distance) may belong to entirely different markets.
2. Diseases that appear in different classes based on a specific taxonomic approach (i.e. ICD-9-CM) may be contiguous in an alternative taxonomic approach.
3. Class 16 is a catch-all group ('symptoms, signs and ill-defined conditions'). Hence distance from and to class 16 is meaningless and ignored in our study.
4. The distance method is independent of our knowledge of drugs: its reliance on external databases constitutes its main strength, as the procedure is objective and can, to a certain extent, be automated. It is however also its weakness, as it is not possible to perform any indepth analysis based on mechanism of action and/or disease pathway.
Alternative measure of exaptation frequency as a robustness check. To compensate for the shortcomings of the distance method and verify its accuracy, we adopted a more qualitative method based on the mechanism of action of the drug and conducted through extensive research on each drug.
According to this qualitative method, FDA and off-label markets are assessed by direct analysis of each of the drug uses. The procedure is the following:
1. As with the distance method, we start from the description of the uses obtained from the DrugDex database.
2. Then we use available sources, such as academic articles, medical databases, Wikipedia articles, books, FDA documents, etc. in order to directly gauge the market difference between the FDA and off-label uses. To do this we look at the mechanism of action, disease description and, when available, historical evidence of drug use.
3. On the basis of this analysis, we code the use with a binary variable Y/N (Y: exaptation confirmed / N: non-exaptation).
In case of conflict between the two methods (the distance and the qualitative) on whether there is exaptation or not, the determination of the qualitative method prevails. Figure 2 maps exaptations based on the two different methods.
Results
Aggregated Results
The preliminary results are shown in Table 1 There are several differences between the 2003 and 2013 samples (see Table 1 
Drug-level results
In figure 4 we show results for off-label and exaptive uses at the drug level for the 2013 sample, which are broadly similar for the 2003 sample. The distributions of all off-label and exaptive uses are highly asymmetric and long-tailed. This is confirmed by a normality test, which confirms that they are not normal. Figure 5 shows a double logarithmic cumulative size-frequency graph of off-label uses per drug. Although the scarcity of points doesn't permit to draw firm conclusions, a KS (KolmogorovSmirnov) test confirms that the distribution may follow a power-law type (Newman 2005) . As it is typical of long-tailed distributions, we note the presence of extreme events such as thalidomide, characterized by a surprising number of 42 off-label uses, all of which are exaptive. In general, we expect that each drug is characterized by a mix of adaptive/exaptive new uses. We also note a correlation between the number of all off-label and exaptive off-label uses (R 
Discussion
We start our discussion section with a short case on 'thalidomide'. The history of this drug encapsulates the essential aspects of our results.
a. A brief history of thalidomide
Thalidomide probably represents the worst tragedy of post-WWII pharmacology history (Stephens and Brynner 2009) . Originally developed as a tranquillizer and morning sickness drug (sold, from 1957, over-the-counter, after seriously deficient animal and human tests), this widely successful drug showed dramatic side effects, such as permanent destruction of peripheral nerves and severe malformation of fetuses (phocomelia). As a result, the drug was withdrawn from the market in 1962. In 1964, in Marseille, Dr. Sheskin was looking for a drug to alleviate the unendurable pain of a condition associated with leprosy: erythema nodosum leprosum (ENL). After exhausting all available drugs, he stumbled upon a discarded bottle of thalidomide. Having nothing to lose with a terminally ill patient, he tried it. The results went beyond any reasonable expectation: not only the pain but the disease itself disappeared. Because of this discovery, 90% of the leprosy hospitals around the world were shut down. Several years later, because some leprosy patients had tuberculosis, and some tuberculosis patients had AIDS (Stephens and Brynner 2009, p. 138) , thalidomide turned out to be effective against several conditions associated with AIDS, such as aphthous ulcers and wasting. Once approved for one condition in 1998, thalidomide could be used for unrelated conditions off-label: "to date, thalidomide has been used to treat 130 disorders, for some of which it is the only effective means of arresting a patient's progressive deterioration" (Stephens and Brynner 2009, p. 164 ).
The thalidomide story shows the three essential features of our results: first, drugs may have divergent and unrelated functions which are often discovered via a serendipitous route. Second, these new uses can be divided into incremental and radical innovations: some uses represent an incremental improvement over existing treatments, whereby others offer treatment for previously incurable diseases. Third, the tight link between adaptive and exaptive developmental routes generates cascades of innovation. Thalidomide was originally developed, adaptively, as a tranquillizer. The multiple exaptations that ensued after the drug's withdrawal from market in 1962 led to research programs devoted to uncover its mechanism of action. This understanding was then used to develop new drugs (as effective as thalidomide but without its terrifying side effects), that in turn enabled the treatment of new diseases. The exaptive/adaptive improvements therefore act to generate cascades of innovations.
b. Radical Exaptations
The impact of exaptations reported in this paper varies greatly between two extremes: radical and incremental. We consider radical those exaptations that 1) offer a treatment for a previously intractable or poorly treated disease; 2) may reveal new scientific and technological trajectories deriving from the discovery of unsuspected possibilities hidden in existing artefacts; and 3) may lead to a cascade of ensuing innovations. The discovery of antisepsis, sedatives, anti-depressants and anesthetics reported in Appendix 1 falls in this category. For instance thalidomide, after the initial catastrophe of phocomelia, collected more than 40 off-label uses. In particular, we find evidence of cascades of exaptive off-label uses. Incremental improvements, on the other hand, add to the current stock of drugs for a specific disease.
The most significant example of the former in our database is represented by thalidomide (see above). Radical exaptive uses generate new markets and revenue streams. We find about 11 examples of radical exaptations in our database, which are illustrated in the table below. Table 2 Our exaptation results enable us to develop this reasoning further. We attempt to estimate the importance of investing in use development in the following way:
<<< Please insert
1. The total number of NMEs approved by the FDA between 1940 and 2011 is 1527. This is a lower boundary for all available NME drugs in the world which includes drugs approved in other countries.
2. The average number of uses per drug is 18 (Walton et al. 2009 ). This number implies that the lower boundary for the total number of uses for existing NMEs is approximately 27000. This number gives us an estimate of the potential supply of solutions available to treat diseases.
We call the set of uses the solution space.
3. Our results based on the 1998 sample of DrugDex database show that about 45% of uses are exaptive. Among the exaptations, about 23% of solutions cross the 2 nd bifurcation, that is, they fall in the same ICD-9-CM general class, whereby the remaining 77% cross the 1 st order bifurcation and fall into a different general class. We call the entire set of diseases and its organization into classes in the ICD-9-CM the 'need space', as it represent the entire set of addressable problems and potential sources of revenues for the pharmaceutical industry. In Figure 7 we show a subset of the need space, namely classes 7 ('diseases of the circulatory systems') and 8 ('diseases of the respiratory system'). In the figure we show the second level partition of diseases for class 8. A drug specifically introduced for a target in class 8 has an average of 18 latent uses. These uses effectively explore the need space: off-label adaptive uses explore the immediate proximity of the focal drug that is the subclasses 'pneumonia and influenza ' (codes 480-488) . This means that they will address conditions similar to the focal drug's FDA-approved uses. Exaptive uses on the other hand explore beyond the adaptive area (in this case the 'pneumonia and influenza sub-subclass') and cross either the 2 nd or 1 st bifurcation. In the former case, they explore other subclasses within class 8 (in Figure 7 this corresponds to all subclasses except 480-488). In the latter case, exaptive uses explore the entire need space outside of class 8. 
Conclusions and ideas for further research
Our paper shows that exaptive processes account for about half of all post-approval innovations in the pharmaceutical industry. Moreover it indicates that exaptations significantly contribute to radical innovation and cascades of change.
In the following, we present some limitations of the current study, we discuss the issue of generalizability to other industries and finish with some implications for innovation theory and practical decision-making driving investment decisions in innovation.
Limitations
Our results are based on the sample of 29 drugs approved by the FDA in 1998, a number that is close to the average number of 27 approved drugs a year. In our sample, we have an extreme event (i.e. low frequency/high impact) -thalidomide, which heavily affects the overall number of off-label and exaptive uses. Is thalidomide an outlier we should get rid of? Our analysis indicates that the distribution of off-label uses is long-tailed (probably power-law). In these distributions, extreme events are not outliers but on the contrary they form a necessary part of the distribution.
Our measure of exaptation treats the FDA-approved use as the benchmark from which to measure the distance to off-label uses. We implicitly assume that the FDA-approved use is the only one developed by the organization that filed for FDA approval. However, except for rare cases (where historical accounts are available), additional uses discovered by the manufacturer are unknown to us.
Hence, we cannot exclude that some uses we classify as off-label were discovered by the organization that filed for FDA approval. The only evidence about this point comes from a previous study (DeMonaco et al. 2006 ) that shows that most off-labels were discovered by users and not manufacturers.
Are our results generalizable?
Are these results generalizable to other industries? Only speculative answers can be given to this question. We expect that, although the numbers will certainly be different across different industries, the following general features will also be found in other sectors:
1. a significant fraction of discovery of new applications happens by the exaptation route;
2. a non-negligible fraction of exaptive discoveries are radical;
3. a non-negligible fraction of exaptive discoveries generate cascades of further innovations.
Several elements support our argument.
Off-label discovery depends predominantly on the role of user innovators. Does the pharma industry differ from other industry with regards to the role of users? Von Hippel and his coauthors (Von Hippel 1988 show that in several sectors a large percentage of innovations are developed by users. Users modify existing products and use them in functionally novel ways to suit their idiosyncratic needs. As these needs emerge from the mix of personal experiences, mental frames, education and activities, they form new contexts that are likely to redefine the ways products are used.
That is, they are likely to trigger exaptations. In the highly regulated pharma industry, supply variety is strongly limited by regulatory approval. Consequently this limits the role of users in the supply of new drugs. However, FDA-approved drugs face significantly less regulations in the off-label market, where users (essentially clinicians, family doctors and patients) are free to explore the full range of potential uses. In one word, regulation limits supply variety but not uses variety. From the viewpoint of uses variety, innovation in pharma does not differ from other sectors where users play an important role.
Exaptations are at their core novel artefact-function associations. Such novel associations derive from the exposure of existing artefacts to new contexts. But, as in complex systems, such as organisms, industrial ecosystems and organizations, the number of new contexts to which an artefact can be exposed is uncountable and the latent uses of an artefact are un-prestateable (Longo et al. 2012) , it follows that the number of artefact-context associations is fundamentally unknowable. This is independent from the type of industrial sector.
R&D is presumed to be guided by the linearity of the goal-driven approach. The reality, however, is that serendipity and chance play a fundamental role, even in science-driven sectors.
Anecdotal evidence suggests that serendipity acts on existing structures, ideas, artefacts, biological entities or institutions, revealing some unforeseen possibilities and connections hidden in them. In other words, serendipity reveals potential exaptations. In principle, as there is no reason to expect that the role of serendipity is fundamentally different across industrial sectors, there is no essential reason to expect that serendipity-driven exaptation be different across industrial sectors.
Implications for innovation and organizations
In this section we discuss two important implications of our research for innovation theory and investment decisions in innovation projects.
a. Exaptation and financial returns
The development of the first anti-depressant (Marsilid) points to an implication of exaptive discovery, which may bear consequences on decision-making processes that drive investment decisions in innovation. Marsilid was developed as an anti-tuberculosis drug and its success exceeded the most optimistic expectations. However, Marsilid also generated an unexpected application as an anti-depressant: in fact, it was the first antidepressant in history. This new use resulted in an unexpected revenue stream whose development cost was zero. In general in any industrial sector, we observe that products that generate new unanticipated uses produce two different revenues streams: a revenue stream generated by investment in the planned use, and a second revenue stream generated by unanticipated uses. It follows that the return on investment for an adaptive project may exceed expectations due to the presence of a stochastic revenue term: the exaptive term.
If investment in a project is likely to yield returns from exaptive discoveries, should the probability of such returns be embedded in the investment decision-making process? This could be achieved by considering two terms: the Return on Investment (ROI) generated by planned use(s), and the ROI generated by exaptive discoveries. The first term is the object of analysis of conventional financial risk analysis tools. But how to deal with the second term?
A starting point could be to calculate an estimate of the probability of exaptation and its statistical properties. Our preliminary results indicate that exaptations follow a long-tailed distribution, probably power law. Such distributions are characterized by the instability of their main moments. This means that the statistical properties of single events may not be knowable with statistical significance. However, the type of event distribution is knowable and this may help plan investment decisions. For instance, De Vany (2004) shows that, in the movie industry, information about the type of long-tailed distribution (e.g. the slope of a power law distribution) gives relevant information about the nature of uncertainty of the phenomenon under inquiry and, consequently, helps plan investment decisions.
The situation of the pharma industry indicates the potential for such an approach. The aggregate value of emergent uses accounts for about 21% of pharma revenues, of which, according to our calculations, about 60% are exaptive. This is a substantial fraction of revenues and should be included as an additional term in the ROI calculations. However, two qualifiers have to be added: first, the incidence of emergent uses varies widely across subsectors; second, within the exaptive uses there is a subclass, the radical uses, that exhibit the potential to generate exceptional returns, such as, Aspirin, botox, minoxidil and, in our database, viagra and thalidomide.
In aggregate, the emergent uses may substantially contribute to the innovativeness, creativity and financial wellbeing of a social system. The measure presented in this paper constitutes the first attempt to quantify such a contributor to innovation.
b. New product development and new use development
At a broader level, the existence and magnitude of the frequency of exaptation described in this paper leads to an important observation-innovation depends on both new product development and new uses development, NPD and NUD respectively. Moreover, new uses represent an important innovation channel that gives rise to significant revenue streams that do not require substantial product modification. However, in organizations as well as in innovation research, there is a pervasive assumption that innovation is the same as NPD emphasized by the lack of mainstream studies documenting the number of new uses per technological artefact.
Building on the distinction between NPD and NUD together with the distinction between adaptive and exaptive processes, we propose the following taxonomy for future research (see figure   9 ):
<<< Please insert Figure Staining agent in microbiology; first fully synthetic drug "Ehrlich began using MB, the first aniline dye, to stain bacteria in 1880. By 1885, upon injecting it into a living frog, …, its nerve fibers were stained blue. Could the chemical dye, he reasoned, affect biological function to interfere with nervous transmission and exert an analgesic, or pain killing, action in people? In 1891 Ehrlich tried MB for malaria. MB worked in mild cases. Nevertheless this represented the first instance of a synthetic drug being successfully used against a specific disease" (Meyers 2007, p. 41) "MB was the very first fully synthetic drug used in medicine. In 1891 it was applied … for the treatment of malaria" (Schirmer et al. 2011, p. e8) 
Penicillin
Antiseptic and lab tool to isolate viruses First large spectrum antibiotic "In addition to its possible use in the treatment of bacterial infections [Fleming referred to external use] , penicillin is certainly useful to the bacteriologist for its power of (influenza) (natural) inhibiting unwanted microbes in bacterial cultures so that penicillin insensitive bacteria can readily be isolated" (Fleming 1929, p. 236 Used in textile industry, patented and branded as Prontosil (Meyers 2007 ) "which had been produced in tons by the dye industry for decades without anyone looking into its antibacterial properties" (Li 2006, p. 51) . Prontosil was discovered to have antibiotics effect by Domagk (Nobel Prize, 1939) FDA (1949) According to the American Cancer Society: "from this disaster [Nazi bombing of Bari harbor in 1943], a chemical agent with anticancer activity was serendipitously discovered" (Meyers 2007, p. 126) . See also Infield (1976) and Mukherjee (Mukherjee 2010 In the early 1950s Laborit discovered the psychiatric effects of Chlorpromazine when he noted that: "our patients are calm, relaxed and euphoric even after major operations; they appear to really suffer less". (Meyers 2007, p. 267) See also (Rouleau and Laborit 1982) "Chlorpromazine revolutionized the specialty of psychiatry. It brought legitimacy to the concept of biological psychiatry by demonstrating that a drug could influence the course of a major psychosis" (Maxwell and Eckardt 1990 involves a potential degeneracy: one Micromedex descriptor may be converted in multiple (indexes p and q) ICD 9 codes. Likewise for FDA descriptors. This is why in step C we select the pair p/q characterized by the minimum class difference in the ICD-9-CM database. For instance, given an NME, if the code relative to an FDA-approved use i falls in class 6 and the codes for an off-label use j falls respectively in class 6 and 7, the off-label use in class 6 is retained. Then weights are assigned to the off-label use and distance between the origin of the ICD-9-CM and the position of the off-label use in the tree is calculated. The distance method inevitably involves an element of judgment in setting the threshold between exaptation and adaptation. We set the bar at the level of second-order bifurcation, that is, at the second digit in the ICD-9-CM classification. ublished on th domide result uses discove Figure 7 -The entire ICD-9-CM database classifies diseases from 1 to 999. For simplicity, the figure shows only two (out of the total of 17) ICD-9-CM classes pertaining to the first level classification. The classes are, respectively, class 7 diseases of the circulatory systems and class 8 diseases of the respiratory systems. For class 8 we report the second level classification, which partitions respiratory system diseases into 6 further subclasses. We do not show further nested sub-subclasses. The red circle represents a hypothetical new (NME) drug designed for a condition that falls in the sub-class pneumonia and influenza. This condition will be classified by a number (or more) between 480 and 488. This drug's emergent (off-label) uses can be divided in three categories depending on the distance from the focal drug (red circle). Based on our earlier calculations, about 450% of new uses will be adaptive meaning that they will effectively explore the proximity of the reference drug in the space 480-488. They are indicated by solid lines starting from the focal drug. About 10-15% will be exaptive crossing 2nd order bifurcations: i.e. they cross the boundary between the pneumonia and influence subclass and the other sub-classes in class 8 (460-519). The third class of exaptive uses will cross 1 st order bifurcation and explore classes (other than 8) of the entire need space (long dash dot line). 
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